Tyson Foods TSN
Consumer Defensive · Agricultural Farm Products · Synthos Deep Dive · 2026-07-03
The Overview
Tyson Foods is the giant company behind a lot of the meat in your grocery store and fast-food restaurants — Tyson chicken, plus Jimmy Dean sausage, Hillshire Farm, Ball Park hot dogs, and Wright bacon. It kills, cuts, and packages beef, pork, and chicken, and turns some of it into ready-to-eat foods.
The problem is that most of what Tyson sells is a commodity: they buy live cattle and hogs at whatever the market charges and sell meat at whatever the market pays, and the gap between those two numbers is thin and swings wildly. Right now the beef part of the business — nearly half of sales — is in a bad stretch because cattle are scarce and expensive, which squeezes profits hard. That's why last year's profit was tiny for a company this size.
On price: the stock looks expensive on last year's depressed earnings but cheap if profits recover to normal. Nobody knows exactly when the cattle cycle turns. Our verdict is Watch — it's a steady, dividend-paying staple, but there's no compelling reason to buy today and we have zero expert insight on it.
Here's what our three scores mean in everyday terms:
- Downside Risk 6/10 (a bit above average). The stock is calm and defensive, but the company carries real debt and its profits are unpredictable, so it's riskier than the sleepy dividend it pays suggests.
- Growth Quality 4/10 (below average). Profits should climb over the next few years — but only because they're bouncing back from a bad year, not because the business is truly growing.
- Exponential Potential 2/10 (very low). This is meat processing. It does not double. Expect a modest dividend-plus-recovery holding, nothing more.
The one big worry: the cattle cycle. Beef margins can stay negative for a long time, and there's no switch Tyson can flip to fix it.
Putting a number on it: our fair-value estimate is $60 against a current price of $55.40 — real upside if our numbers are right.
Our summary metrics
Low beta (0.39) & defensive staple, but net-debt/EBITDA 3.0×, 45× trailing on trough earnings, and brutal commodity cyclicality.
Forward EPS recovery is real (~15% CAGR off a trough) but it's a cyclical bounce, not secular growth; 6.5% gross margin, ~2.5% ROE.
Commodity protein processor at $21B in a mature, low-margin category — no acceleration, no TAM expansion. This is a compounder-of-cattle-cycles, not an exponential.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Commodity protein processor at $21B in a mature, low-margin category — no acceleration, no TAM expansion. This is a compounder-of-cattle-cycles, not an exponential.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $73 (high $78 / low $63; 0 Strong Buy · 15 Buy · 14 Hold · 1 Sell) — context, not our anchor |
| Valuation | 45× trailing EPS · 15× FY26E · 13× FY27E · 9× FY29E · EV/EBITDA 11.2× · EV/Sales 0.51× · P/B 1.15× |
| Technicals | Downtrend/base — $58.89, −14% off 52-wk high, below both 50-DMA ($61.9) & 200-DMA ($59.5), RSI 66, +2.7% 12-mo (SPY +20.6%) |
| Conviction | Low — 0 expert voices, 0 KB claims; this is a screen-driven fundamentals note, nothing more |
| Position sizing | If owned at all: income/defensive satellite, ≤2%; a dividend holding, not a growth bet |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for TSN — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $55.40, 4% below the 50-day average ($58), 8% below the 200-day average ($60) — a downtrend. 19% below the 52-week high of $69, 9% above the 52-week low of $51.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $55.40 is currently inside the band (band $55–$60).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 37.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.26, negative momentum.
Relative performance vs S&P 500 & its sector (XLP (sector)), set to 100 a year ago
Solid = TSN · dashed = S&P 500 · dotted = XLP (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Tyson Foods (NYSE: TSN) is the largest US and one of the largest global producers of protein, founded 1935, headquartered in Springdale, Arkansas, ~138,000 employees. It operates four commodity/branded protein segments plus corporate. Fiscal year ends late September (FY2025 closed 2025-09-27).
The business is a vertically integrated meat packer: in Beef and Pork it buys live cattle/hogs and fabricates carcasses into cuts and case-ready product; in Chicken it raises and processes poultry; and in Prepared Foods it makes higher-margin branded convenience items (Jimmy Dean, Hillshire Farm, Ball Park, Wright, State Fair, Aidells, plus the Tyson and ibp labels).
Revenue mix (FY2025, $54.4B total, from segment filings):
- By segment: Beef $21.6B (40%) · Chicken $16.8B (31%) · Prepared Foods $9.9B (18%) · Pork $5.8B (11%) · Corporate & Other $2.3B.
- By geography: FMP provides only a single historical export line (FY2023 export sales ~$5.1B); the business is overwhelmingly US-domestic, so this is a US-consumer / US-cattle-supply story, not an international one.
The structural tell is right there in the mix: ~50% of revenue (Beef + Pork) is pure commodity spread with razor-thin, cycle-driven margins; the durable-margin value sits in Chicken and Prepared Foods. That split governs everything below.
2. The expert thesis — (none on file)
There is no expert coverage of Tyson Foods in the Synthos knowledge base: total_claims = 0, net-bullish voices = 0. No net-bullish or cautionary voice in our panel has a traceable, dated claim on TSN.
Per house standard we say this plainly rather than manufacture conviction: this verdict is entirely fundamentals- and quant-driven. Nothing in the sections below cites a claim_id, because none exists. The absence is itself signal — the expert panels Synthos tracks (technology, biotech, macro, quality-compounding) simply do not spend time on a commodity meat packer, which is consistent with our own read that TSN is a cyclical staple, not a forward exponential.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 6 · Moderate-High | Beta 0.39 and a defensive staple category argue safe; but net-debt/EBITDA 3.0×, 45× trailing on trough earnings, a −41% peak-to-trough drawdown in the history, and structural beef-cycle cyclicality pull it the other way. Not the low-risk bond-proxy the yield implies. |
| Growth Quality | 4 · Below Average | Forward EPS CAGR looks strong (~15% FY25→FY29E) but it's a recovery off a depressed base, not secular growth. 6.5% gross margin, ~2.5% ROE, ~2.7% ROIC — returns on capital are structurally poor. Prepared Foods & Chicken are the only quality legs. |
| Exponential Potential | 2 · Very Low | Mature category, no TAM expansion, no acceleration (2nd derivative of growth is cyclical, not compounding). A $21B commodity processor does not multibag. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Cattle cycle turns; Beef margins normalize faster than expected; Chicken stays strong; Prepared Foods holds. FY27E EPS beats to ~$5.00 (vs $4.48 cons); market pays a mid-cycle ~15.5×. | ~$78 (+32%) |
| Base (our anchor) | Estimates roughly hit — FY26E EPS $4.04, FY27E $4.48; a mid-cycle protein packer earns ~13.5× on a ~$4.45 blended forward number. | ~$60 (+2%) |
| Bear | Beef trough persists into FY27; Chicken feed costs rise; consumer trades down from branded prepared foods. FY27E EPS misses to ~$3.50; multiple de-rates to ~12×. | ~$42 (−29%) |
Synthos fair value = the base case, ~$60 (+2%), with the full $42–$78 span as the honest range. Our anchor sits well below the Street's $73 consensus because the Street is underwriting a cleaner and faster beef-cycle recovery than we are willing to assume with zero expert edge and a segment still in a margin trough. The stock is, in our read, roughly fairly valued today — which is exactly why the verdict is Watch, not Buy. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). TSN is neither — it is a cyclical commodity processor, which is a third category entirely:
- Forward growth: revenue CAGR FY25→FY29E is only ~2.8% ($54.4B → $60.7B est) — this business barely grows the top line. EPS growth looks better (~15% CAGR) purely because the FY25 base was a cyclical trough (GAAP EPS $1.36, adjusted ~$3.81).
- Acceleration (the 2nd derivative) is cyclical, not secular: the forward EPS path ($4.04 → $4.48 → $5.67 → $6.59) is a recovery slope off a beaten-down year, driven by cattle-supply normalization — not a self-reinforcing growth flywheel. When the cycle rolls over again, so does the "acceleration."
- Room to run: the US protein market is mature and share-saturated — Tyson already is the largest player. There is no TAM expansion story; volume grows with population and protein-per-capita, low single digits. At $21B market cap the constraint isn't size, it's the absence of a growth vector.
- Reinvestment runway: capex is maintenance-heavy (~$1B/yr, ~0.7× depreciation), FCF is real (~$1.2B FY25) but goes largely to the dividend (~$0.70B) and modest buybacks — a return-of-capital profile, not a reinvest-and-compound one.
Exponential Potential: Very Low (2/10). Own TSN, if at all, for a ~3.4% dividend and a possible mid-cycle earnings recovery — never for growth. This honest framing is why TSN would sit in a Value/Income sleeve, not the Flagship exponential queue.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $54.44B, +2.1% (FY24 $53.31B; FY23 $52.88B). Flat, mature top line — protein volume plus modest pricing.
- The trough is real: FY25 net income $474M (0.9% net margin), GAAP EPS $1.36 — down from FY24's $800M / $2.31 and a fraction of the FY22 peak ($3.24B / $9.18). FY23 was an outright loss (−$648M) on a beef/pork collapse. This is a business whose bottom line swings 5–10× across a cycle.
- Margins (FY25): gross 6.5%, EBITDA 4.6%, operating 2.6%, net 0.9% — commodity-processor economics. Prepared Foods and Chicken carry the profit; Beef/Pork are near breakeven at trough.
- Recent quarterly trajectory (FY26, FY ends Sept): Q1'26 rev $14.31B / EPS $0.25; Q2'26 rev $13.65B / EPS $0.75 (adj $0.87 beat vs $0.78 est). Sequential EPS improvement is the early recovery tell — but off a very low bar.
- Cash flow: FY25 operating CF $2.16B, capex −$0.98B, FCF ~$1.18B (FCF yield ~5.9%). FCF covers the dividend (~$697M) with room; that's the defensive floor.
- Balance sheet: total debt $8.83B, cash $1.23B, net debt $7.60B, net-debt/EBITDA ~3.0× — elevated for a cyclical, and the single most important risk metric here. Current ratio 1.83×, investment-grade but not a fortress.
- Returns on capital: ROE ~2.5%, ROIC ~2.7%, ROA ~1.3% — structurally low, cycle-depressed. Even mid-cycle these top out modestly.
6. Valuation — priced in or room?
TSN is the mirror image of a growth-stock valuation puzzle: it looks expensive on trailing (45× trough EPS) and cheap on forward if the cycle turns — 15× FY26E → 13× FY27E → ~9× FY29E. The whole valuation debate is one question: do you believe the beef cycle normalizes on the analyst timeline?
- On multiples that don't depend on the E: EV/EBITDA 11.2×, EV/Sales 0.51×, P/B 1.15× — all middling-to-slightly-rich for a low-return processor. The FMP letter rating is B− (overall score 2/5), dragged by a P/E score of 1/5.
- Dividend: $2.03/yr, yield ~3.4%, but the TTM payout ratio is >100% of trough GAAP earnings — sustainable only because FCF (not GAAP EPS) covers it, and only if earnings recover. Watch this if the trough deepens.
- Reverse read: at $58.89 the market is paying ~13× a ~$4.50 mid-cycle number — i.e. it already prices in a partial recovery. Little is left for the buyer unless the recovery over-delivers.
- Street targets (context): consensus $73, high $78, low $63 (15 Buy / 14 Hold / 1 Sell). Our $60 base FV is below consensus because we discount the recovery more heavily. Not a value screaming buy; a fairly-valued cyclical staple.
7. Technicals (from the tech block)
- Trend: weak. $58.89 sits below the 50-DMA ($61.90) and roughly at the 200-DMA ($59.47) — no uptrend; a sideways-to-down base. MACD −0.91 (negative).
- Location: −14.3% off the 52-week high ($68.75), +16.1% off the 52-week low ($50.72) — mid-range, not extended. The longer history carries a −40.6% max drawdown from peak, a reminder of how deep this name can cut.
- Momentum: RSI(14) 66 — firm and approaching overbought (<70), reflecting a recent bounce off lows, but on a weak trend.
- Relative strength (the tell): TSN +2.7% 12-mo vs SPY +20.6% and QQQ +30.3%; −8.4% 3-mo vs SPY +13.7%. Persistent, heavy underperformance of the market — classic defensive laggard.
- Read: technicals do not confirm a buy. Below the 50-DMA, badly lagging the market, with a firm-but-not-broken RSI on a weak trend. No urgency; a base, not a launchpad.
8. Moat & competitive position
Tyson's edge is scale and distribution, not a durable moat. Its advantages: the largest US protein processing/logistics footprint, well-known Prepared Foods brands (Jimmy Dean, Hillshire Farm, Ball Park — the genuine pricing-power leg), and deep retail/foodservice relationships. But the Beef/Pork ~50% of revenue is a commodity spread business with essentially no moat — margins are set by cattle/hog supply and packer capacity, not by Tyson. In a live-cattle shortage (the current condition), even the biggest packer earns thin or negative beef margins. The Chicken segment is better (branded + vertical integration) but still competitive.
Peer set (market cap, FMP): Bunge Global $20.7B (ag commodities), US Foods $23.0B (distribution), Church & Dwight $23.4B (branded staples), McCormick $14.4B (branded), Smithfield Foods $9.7B (direct pork/protein comp), Dollar Tree $23.8B, FEMSA $44.1B, Coca-Cola FEMSA $22.6B, Somnigroup $16.5B. The most instructive comps are Smithfield (pure protein, similar cyclicality) and Bunge (ag commodity margins) — both remind you this is a low-multiple, spread-driven category, not a branded-staple compounder like CHD or MKC.
9. Management, capital allocation & guidance
- Capital allocation: disciplined and return-of-capital tilted — ~$1B/yr maintenance capex, ~$697M dividend, modest buybacks (~$196M FY25), and net debt paydown (−$1.09B long-term debt repaid FY25). Sensible for a cyclical: deleverage in the trough, protect the dividend. Net-debt/EBITDA ~3.0× is the constraint on getting more aggressive.
- Insider activity: the sampled window shows routine grants and tax-withholding (F-InKind) dispositions by newly-titled COOs (Wes Morris Form 3; Devin Cole Form 4 F-InKind at ~$68), plus option grants — no discretionary open-market selling cluster that would signal a view. Neutral.
- Management's own guidance (the earnings-call track): we pulled the latest SEC 8-K (Item 2.02, filed 2026-05-04 for Q2'26). The 8-K body is cover/exhibit boilerplate only — it furnishes the press release as Exhibit 99.1 but does not contain the guidance text itself, and no revenue/outlook figures are in the machine-readable filing. Per house standard we therefore report that management's forward guidance was not available from the free SEC route for this note; we do not fabricate it. (The segment-level FY26 outlook lives in the exhibit/earnings deck, which is outside this feed.)
10. Catalysts & what to watch
- Next earnings: 2026-08-03 (Q3'26; Street EPS $1.04, revenue ~$14.1B). The key line: Beef segment operating margin (still negative/breakeven?) and any management signal on cattle-supply timing.
- The cattle cycle: USDA cattle-inventory and placement data — the single macro variable that decides the Beef segment (and ~40% of revenue).
- Chicken feed costs: corn/soybean-meal prices drive the best-margin volume leg.
- Prepared Foods volume/mix: are branded convenience foods holding price as the consumer trades down? The quality-margin tell.
- Deleveraging: continued net-debt/EBITDA progress below 3× would de-risk the dividend and the equity.
Thesis tripwires (what would change the call): a clear cattle-cycle turn (Beef margin back to mid-cycle) would push us toward Buy — Tactical; a deepening trough that pressures the dividend or pushes net-debt/EBITDA above ~3.5× would push us toward Avoid.
11. Key risks
- Cattle-cycle / commodity cyclicality (structural, the big one): ~50% of revenue is a live-animal spread business; Beef margins are trough and can stay there for quarters. FY23's outright loss shows the downside.
- Leverage: net-debt/EBITDA ~3.0× on a cyclical means a deeper trough compounds equity risk and pressures the dividend.
- Trough-earnings valuation: 45× trailing leaves the stock exposed if the recovery slips; the forward "cheapness" is entirely recovery-dependent.
- Consumer trade-down: in a weak consumer, shoppers move from branded Prepared Foods to private label, eroding the one high-margin leg.
- Input & disease risk: feed-cost spikes, avian influenza / animal-disease outbreaks, and trade/tariff shifts on protein exports.
- No expert edge: we hold zero traceable conviction on this name — the verdict rests solely on quant/fundamentals, which warrants humility and a Watch.
12. Verdict, position sizing & monitoring
Watch. Tyson is a well-run, defensive, dividend-paying staple — but at $58.89 it is roughly fairly valued on our numbers (base FV ~$60), its earnings are in a commodity trough, its "growth" is a cyclical bounce rather than secular compounding, it carries ~3.0× net leverage, and it lags the market badly on every trailing window. Crucially, we have no expert conviction on it: zero KB claims. That combination — fair value, cyclical, no edge — is the textbook definition of Watch, not Buy.
- Sizing: if held at all, an income/defensive satellite ≤2%, owned for the ~3.4% yield and optional beef-cycle recovery — never as a growth position. We are not adding it to the Flagship.
- Monitoring: re-underwrite on the tripwires in §10 — a confirmed cattle-cycle turn flips this toward Buy — Tactical; a dividend-threatening trough flips it toward Avoid. Formal re-score each earnings print.
- Single biggest risk: the cattle cycle — Beef is ~40% of sales, in a margin trough, and Tyson cannot fix supply.
This verdict is logged as a tracked Synthos call as of 2026-07-03 at $58.89.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage of TSN in the Synthos knowledge base. No
claim_idis cited because none exists; conviction here is explicitly quant/fundamentals-only. Fabricated conviction is structurally impossible (claim-ID reconciliation). - Data as-of: fundamentals 2026-03-28 (Q2'26; FY ends late Sept) · estimates & prices 2026-07-03 · no expert claims on file. Forward figures are analyst consensus (FMP), labeled as estimates. Note FY25 GAAP EPS ($1.36) differs from adjusted/consensus EPS (~$3.81) used in the forward multiples.
- Management caveat: management's own forward guidance was not available from the free SEC 8-K route for this note (the 2026-05-04 filing furnishes the earnings release as an exhibit but contains no guidance text); we do not fabricate it.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").